SG10201913690SA - Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use - Google Patents
Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of useInfo
- Publication number
- SG10201913690SA SG10201913690SA SG10201913690SA SG10201913690SA SG10201913690SA SG 10201913690S A SG10201913690S A SG 10201913690SA SG 10201913690S A SG10201913690S A SG 10201913690SA SG 10201913690S A SG10201913690S A SG 10201913690SA SG 10201913690S A SG10201913690S A SG 10201913690SA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- staphylococcus aureus
- specifically bind
- alpha toxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/709—Toxin induced
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440581P | 2011-02-08 | 2011-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913690SA true SG10201913690SA (en) | 2020-03-30 |
Family
ID=46639171
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913690SA SG10201913690SA (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| SG10201600899PA SG10201600899PA (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| SG2013057831A SG192212A1 (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201600899PA SG10201600899PA (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| SG2013057831A SG192212A1 (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9527905B2 (https=) |
| EP (2) | EP2673373B3 (https=) |
| JP (4) | JP2014508748A (https=) |
| KR (1) | KR101993839B1 (https=) |
| CN (2) | CN103443285B9 (https=) |
| AU (1) | AU2012214531C1 (https=) |
| BR (1) | BR112013020086B1 (https=) |
| CA (1) | CA2826566C (https=) |
| CY (1) | CY1121389T1 (https=) |
| DK (1) | DK2673373T6 (https=) |
| ES (1) | ES2709065T7 (https=) |
| HR (1) | HRP20182017T4 (https=) |
| HU (1) | HUE040734T2 (https=) |
| LT (1) | LT2673373T (https=) |
| MX (3) | MX345285B (https=) |
| PL (1) | PL2673373T6 (https=) |
| PT (1) | PT2673373T (https=) |
| RS (1) | RS58190B2 (https=) |
| RU (1) | RU2620065C2 (https=) |
| SG (3) | SG10201913690SA (https=) |
| SI (1) | SI2673373T1 (https=) |
| SM (1) | SMT201800635T1 (https=) |
| TR (1) | TR201817932T4 (https=) |
| WO (1) | WO2012109285A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014100111A (ru) | 2011-06-10 | 2015-07-20 | МЕДИММЬЮН, ЭлЭлСи | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ |
| HRP20201370T1 (hr) | 2011-11-07 | 2020-11-27 | Medimmune Limited | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule |
| WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| BR112015010240A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Ltd | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas |
| BR112015010125A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| KR20210083389A (ko) * | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| RU2016119052A3 (en) * | 2013-10-17 | 2018-09-10 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody sequences |
| WO2015109012A1 (en) * | 2014-01-14 | 2015-07-23 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| US20180017559A1 (en) * | 2014-08-12 | 2018-01-18 | Arsanis Biosciences Gmbh | Predicting s. aureus disease |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| JP6889701B2 (ja) | 2015-09-24 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルファ溶血素バリアント |
| WO2017075188A2 (en) * | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| WO2018148494A1 (en) | 2017-02-09 | 2018-08-16 | Bluefin Biomedicine, Inc. | Anti-ilt3 antibodies and antibody drug conjugates |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN109384844B (zh) * | 2017-08-04 | 2020-12-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用 |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| US11396542B2 (en) | 2018-08-21 | 2022-07-26 | Synkrino Biotherapeutics, Inc. | Astrotactin1-based compositions and pharmaceutical formulations |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
| CN113811544A (zh) * | 2019-03-13 | 2021-12-17 | 免疫医疗有限责任公司 | 减少定殖患者中的金黄色葡萄球菌感染 |
| WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
| CN112538112B (zh) | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444173A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| KR20230147616A (ko) * | 2021-01-11 | 2023-10-23 | 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 | 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용 |
| CN112941136B (zh) * | 2021-03-24 | 2023-04-28 | 成都欧林生物科技股份有限公司 | 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法 |
| CN114455048B (zh) * | 2022-03-02 | 2023-03-14 | 江苏微导纳米科技股份有限公司 | 一种桨杆 |
| CN117106077B (zh) * | 2022-04-28 | 2024-07-16 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| CN116023486B (zh) * | 2023-01-10 | 2024-10-08 | 西北农林科技大学 | 金黄色葡萄球菌α-溶血素纳米抗体、制备方法及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP2000510582A (ja) | 1996-04-25 | 2000-08-15 | ゼニコン・サイエンシーズ・コーポレーション | 微粒子標識を使用した分析物アッセイ |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ATE458006T1 (de) * | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) * | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| NZ553776A (en) * | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
| JP2009526520A (ja) | 2006-01-17 | 2009-07-23 | バイオレックス セラピュティックス インク | 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法 |
| TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| US20080131457A1 (en) * | 2006-06-12 | 2008-06-05 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| WO2009029132A2 (en) * | 2007-05-31 | 2009-03-05 | Merck & Co., Inc. | Antigen-binding proteins targeting s. aureus orf0657n |
| PL2188313T3 (pl) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| JP5658564B2 (ja) * | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| US8172115B1 (en) | 2008-04-10 | 2012-05-08 | Spencer Forrest, Inc. | Hair building solids dispenser for one handed operation |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| GB2467939A (en) * | 2009-02-20 | 2010-08-25 | Univ Sheffield | Removal of bacteria from media |
| SA110310528B1 (ar) * | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
-
2012
- 2012-02-07 PT PT12745207T patent/PT2673373T/pt unknown
- 2012-02-07 EP EP12745207.6A patent/EP2673373B3/en active Active
- 2012-02-07 JP JP2013553501A patent/JP2014508748A/ja active Pending
- 2012-02-07 SG SG10201913690SA patent/SG10201913690SA/en unknown
- 2012-02-07 HU HUE12745207A patent/HUE040734T2/hu unknown
- 2012-02-07 LT LTEP12745207.6T patent/LT2673373T/lt unknown
- 2012-02-07 MX MX2013009127A patent/MX345285B/es active IP Right Grant
- 2012-02-07 CN CN201280007986.4A patent/CN103443285B9/zh active Active
- 2012-02-07 CA CA2826566A patent/CA2826566C/en active Active
- 2012-02-07 EP EP18190790.8A patent/EP3470526A3/en active Pending
- 2012-02-07 DK DK12745207.6T patent/DK2673373T6/da active
- 2012-02-07 CN CN201710480750.7A patent/CN107474133B/zh active Active
- 2012-02-07 AU AU2012214531A patent/AU2012214531C1/en active Active
- 2012-02-07 US US13/983,804 patent/US9527905B2/en active Active
- 2012-02-07 BR BR112013020086-3A patent/BR112013020086B1/pt active IP Right Grant
- 2012-02-07 SG SG10201600899PA patent/SG10201600899PA/en unknown
- 2012-02-07 SM SM20180635T patent/SMT201800635T1/it unknown
- 2012-02-07 TR TR2018/17932T patent/TR201817932T4/en unknown
- 2012-02-07 RS RS20181450A patent/RS58190B2/sr unknown
- 2012-02-07 HR HRP20182017TT patent/HRP20182017T4/hr unknown
- 2012-02-07 PL PL12745207T patent/PL2673373T6/pl unknown
- 2012-02-07 RU RU2013141134A patent/RU2620065C2/ru active
- 2012-02-07 MX MX2017001101A patent/MX375113B/es unknown
- 2012-02-07 ES ES12745207T patent/ES2709065T7/es active Active
- 2012-02-07 WO PCT/US2012/024201 patent/WO2012109285A2/en not_active Ceased
- 2012-02-07 SI SI201231470T patent/SI2673373T1/sl unknown
- 2012-02-07 SG SG2013057831A patent/SG192212A1/en unknown
- 2012-02-07 KR KR1020137023512A patent/KR101993839B1/ko active Active
-
2013
- 2013-08-07 MX MX2020009700A patent/MX2020009700A/es unknown
-
2017
- 2017-02-13 JP JP2017023905A patent/JP6367393B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127340A patent/JP6723293B2/ja active Active
- 2018-11-28 CY CY20181101266T patent/CY1121389T1/el unknown
-
2020
- 2020-06-23 JP JP2020108083A patent/JP7047017B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913690SA (en) | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use | |
| IL272831A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| ZA201403492B (en) | Antibodies specific for trop-2 and their uses | |
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
| AP2013007135A0 (en) | Anti-sclerostin antibody crystals and formulationsthereof | |
| ZA201402172B (en) | Anti-htra1 antibodies and methods of use | |
| EP2874650A4 (en) | FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF | |
| SG11201502757QA (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| IL231061A0 (en) | Antibacterial compounds and methods for use | |
| ZA201407330B (en) | Cross-reactive staphylococcus aureus antibody | |
| IL244936A0 (en) | Cross-reactive staphylococcus aureus antibody sequences | |
| EP2827902A4 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD19 ANTIBODY | |
| IL246160A0 (en) | Antibodies directed against the toxin (lukgh (lukab) of staphylococcus aureus and antibody sequences | |
| PL2844275T3 (pl) | Koagulazy gronkowcowe stanowiące antygeny i sposoby ich zastosowania | |
| GB201121564D0 (en) | Use of antibody |